Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Biogen Inc.
BIIB
NASDAQ·Healthcare·Drug Manufacturers - General·Mkt cap $31.0B
$215.56
▲ +2.77%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$121.05 - $219.72
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 57.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Advanced neurological research capabilities
- Extensive proprietary drug development pipeline
- Strong intellectual property portfolio
- Strategic research collaborations
Bear Case
1 risk
- Low volatility (beta 0.2).
Growth
Mild headwinds expected
Expansion of Alzheimer's treatment market
Value
Fairly valued vs Large Cap Pharma peers
Momentum
Strong
+18.3% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying BIIB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Jul 29, 2026
APR 29, 2026
Reported EPS of $3.57 vs $3.05 consensus (+17.1% surprise). Revenue of $2.5B vs $2.3B expected (+8.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+17.1%
Next: Jul 29, 2026
Revenue trend · last 8Q
—
—
+3%
+6%
+7%
-0%
-7%
+2%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$2.5B
$2.5B
$2.5B
$2.4B
$2.6B
$2.5B
$2.3B
$2.5B
Margins · last 8Q
Gross
73.3%
Operating
16.0%
Profit
12.9%
Wall Street consensus
19 analysts · 58% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
58%
Hold
37%
Sell
5%
Median Price Target
$222.00
▲ +3.0% vs $215.56
Latest: Cantor Fitzgerald · Jun 22, 2026
6 analysts covering
vs Industry
How BIIB stacks vs Drug Manufacturers - General
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related